The Readout LOUD

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Vertex’s polarizing data, Aduhelm’s adieu, & an FDA icon

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

The plight of the VC, Gilead’s latest setback, & more M&A

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Biotech layoffs, slumping stocks, and a 2024 preview

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Live! From JPM 2024

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

2023 in review, CEO report cards, and a look at the year ahead

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

CRISPR history, biotech struggles, & a big week for deals

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

The Readout LOUD Allison DeAngelis and Adam Feuerstein

A CRISPR milestone, algorithms amok, & biotech mixology

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Lilly’s obesity drug, the power of radiation, & a biotech implosion

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Decoding biotech hype, the Sarepta saga, & au revoir to a CEO

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

ESMO highlights, Roivant’s big deal, & biotech VC on the rise

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Live from the 2023 STAT Summit

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Merger Mondays, Ozempic panic, & CRISPR’d pigs

The Readout LOUD Damian Garde and Allison DeAngelis

Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech’s slump

The Readout LOUD Damian Garde and Allison DeAngelis

A thorny ALS debate at the FDA, and the promise of artificial wombs

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Covid’s latest surge, Alnylam at the FDA, & the end of an era

The Readout LOUD Damian Garde and Adam Feuerstein

Back to school for biotech, Biogen’s potential pivot, & Illumina’s next chapter

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Vivek’s star turn, leaky drug data, & biotech as family business

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Racing for gene therapy, a pioneering approval, & startups in the lurch

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Your guide to Wegovy’s blockbuster heart study

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Biotech layoffs, eye drug drama, & gene therapy milestones

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Biogen’s sticky situation, Wegovy’s risks, & biotech insider trading

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

BridgeBio’s big week, Lilly’s Alzheimer’s data, & succession at Stanford

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Wegovy in the brain, pivotal Alzheimer’s data, & pulling Threads

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Novavax’s CEO promises a turnaround & how Lilly roiled the obesity market

The Readout LOUD Damian Garde and Meg Tirrell

Messy PBM conflicts, debatable vaccines, & the future of flu season

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Biogen’s messy board, Laronde’s data problem, & the downside of a boom

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Merck v. USA, the best of ASCO, and Leqembi at the FDA